Results 101 to 110 of about 61,616 (223)

Patient‐reported outcomes, postoperative pain and pain relief after day‐case surgery (POPPY): short‐term peri‐operative analgesic use

open access: yesAnaesthesia, Volume 81, Issue 8, Page 1057-1067, August 2026.
Summary Introduction An increasing proportion of complex surgical procedures are being performed in the UK as day‐cases, with variable and limited follow up. Discharge prescriptions must provide adequate analgesia, while considering the safety of the patient and public, following best practice guidance and good opioid stewardship.
Anna Ratcliffe   +2083 more
wiley   +1 more source

Risks of gynecological and breast cancers in women with endometriosis or adenomyosis: A nationwide cohort study

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 8, Page 1607-1613, August 2026.
Endometriosis (including adenomyosis) is an inflammatory disease with lesions of endometrial tissue outside the uterus or in the uterine wall. In this study on Swedish women, endometriosis or adenomyosis was associated with persistently increased risks of breast and epithelial ovarian cancers, especially clear cell, endometrioid, and low‐grade serous ...
Louise Moberg   +6 more
wiley   +1 more source

Long‐Term Cancer and Mortality After Thymectomy

open access: yesEuropean Journal of Neurology, Volume 33, Issue 8, August 2026.
In a propensity score‐matched study comparing 398 thymectomy patients with 398 cardiothoracic controls over 10 years, thymectomy was not associated with excess all‐cause mortality (HR 0.78; 95% CI 0.54–1.13) or new malignancy (4.3% in both groups). Indication‐stratified analysis revealed heterogeneity: thymic malignancy carried significantly higher ...
Shahar Shelly   +7 more
wiley   +1 more source

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 450-459, 15 July 2026.
What's new? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy